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administration to patients su?en'ng from acute central ner
vous system oxidation as occurs in a stroke or from gradual
central nervous system oxidation which can exhibit itself as

progressive central nervous system function loss.
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2
and n is a whole integer from 1 to 5 or

2,4-DISULFONYL PHENYL BUTYL
NITRONE, ITS SALTS, AND THEIR USE AS
PHARNIACEUTICAL FREE RADICAL TRAPS

BACKGROUND OF THE INVENTION
This invention relates to a particular nitrone compound
and its salts and their advantageous use as pharmaceutical

nitrone free radical trapping agents.
BACKGROUND INFORMATION

and Y is tert-butyl or a hydroxylated or acetylated tert-butyl
or a substituted phenyl. These compounds were proposed as
10 pharmaceutical agents to treat the aftermath of stroke and

other conditions reported to be associated with free radical

damage.

Alpha-phenyl tert butyl nitrone

In 1992 we ?led a second PCT patent application on PBN

O

and related compounds and their medical use. This applica
tion, based on prior US. patent application Ser. No. 716,952
(?led Jun. 18, 1991) and abandoned on Apr. 26, 1993, was
published on Dec. 23, 1992 as WO 92/22290. This 1992

or “PBN”) was identi?ed in the 1970s as a useful analytical

reagent to be used in conjunction with electron spin reso
nance (“ESR”) to aid in the detection of free radicals. PBN

publication provided two extremely broad and general dis
20

was found to react with certain free radicals and generate a

chemical species yielding a characteristic ESR spectrum and
thus making it possible to determine the presence or absence
of free radicals
In the late 1970s and early 1980s the medical community
began to focus on the roles played by free radicals in

closures. First, it attempted to describe as many disease
states as possible which were associated with free radicals.

These ranged from CNS conditions (including stroke, aging,

migraine, etc.) through peripheral organ disease (including
25

diseases such as heart attacks, strokes and the like. PBN was

atherosclerosis, bed sores, wounds, and muscle overexer
tion) through UV exposure, to mention but a few highlights.
Second, it attempted to list as many potential spin traps as

possible.

used increasingly in vitro to provide analytical evidence of

In addition to a whole range of non-PEN materials, this

the presence of free radicals in these settings. It was also
later administered in vivo in animal models, again as an

application greatly expanded the de?nition of potentially
useful PBN compounds to include PBN, and derivatives
thereof of the formula

analytical adjunct in attempts to observe free radicals during
ischemia simulations and the like.

In the mid 1980s, the ?rst possible therapeutic eifects of
PBN were implied when severe trauma ischemia animal 35
tests showed that PEN-treated animals were more likely to

survive than controls.

On May 2, 1991, our PCT patent application WO-9l
05552 was published. This patent application, which in part
corresponds to now-issued US. Pat, Nos. 5,025,032 and
5,036,097, described PBN and a family of PBN derivatives
de?ned by the formula

wherein

X is phenyl, imidazolyl, phenothiazinyl or
(112)”

H

X

O

\
/
C=N+
/
\

wherein

45

Y

n=1—5, preferably l—3;
R2=independently (can vary within the molecule) halogen,

X is phenyl or
50

(011)»

alkyl, oxyalkyl, alkenyl, oxyalkenyl, OH, NHZ, NHZ,
NZZ, NO,

55

where R is H,
0

ll
Z—C—

or Z; or

—SO3H, —OSO3H, SH, —S(alkyl), —S(alkenyl, and
haloalkyl, speci?cally including —CF3;

O

AIO or S; and

—CI—I=N
Y

65

Z is a C1 to C6 straight, branched, alkyl or cyclic group; and
Y is a tert-butyl group that can be hydroxylated or acetylated
at one or more positions; phenyl or

5,488,145
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acute oxidative damage to the central nervous system, such
as a patient who has suffered a stroke, in which a pharma
ceutical composition based on this compound or its salt is

(112)"

administered intravenously.
In a fourth aspect, this invention provides a method for

treating a patient suffering from a condition characterized by
protracted low grade oxidative stress upon the central ner

PBN was stated to be the most preferred compound at that
time, being said to have no measurable effect on normal or

vous system and progressive loss of central nervous system

uninjured cells, and a number of derivatives were also stated
to be useful, including hydroxy derivatives, especially 2-, 3- I

function. In this method, a pharmaceutical composition
based on this compound or its salt is administered intrave

or 4-hydroxypheny1 t-butyl nitrone and phenyl (mono-, di
or trihydroxy) tert-butyl nitrone; PBN esters, especially
esters which release 2-, 3-, or 4-hydroxyphenyl t-butyl

nously or preferably orally.
DETAILED DESCRIPTION OF THE
INVENTION

nitrone such as acetoxy derivative; 2-, 3-, or 4-carboxyphe

nyl t-butyl nitrone; phenyl hydroxybutyl nitrone; alkoxyl

This Detailed Description is arranged into the following

derivatives, especially alkoxyl derivatives which release 2-,
3-, or 4-hydroxyphenyl t-butyl nitrone, for example, the 2-,
3-, or 4-methoxyphenyl derivatives of PBN; and acetarnide
derivatives, especially acetamide derivatives which release
2-, 3-, or 4-aminophenyl t-butyl nitrone; diphenyl nitrone
(PPN) and the analogous diphenyl nitrone derivatives;

sections:

Brief Description of Drawings.
The Compounds and Salts.
20

Compound Preparation.
Pharmaceutical Compositions.

N-tert-butyl-ot-(4-nitro-phenyl) nitrone; and N-tert-butyl-ot
(2-sulfophenyl) nitrone.

Conditions Treated and Treatment Regimens.

Examples.
STATEMENT OF THE INVENTION

25

BRIEF DESCRIPTION OF THE DRAWINGS

We have now discovered that one particular PBN deriva

tive and its salts have unexpectedly superior pharmacologi

In this speci?cation reference will be made to the accom

cal properties. Although this derivative, 2,4-disulfonyl PBN,

panying drawings in which

falls within the broad family of materials generally
described in the aforementioned WO 92/022290 publication,
it is not speci?cally disclosed. Neither are its advantageous

prepare the compound.
FIGS. 2 (A, B and C) and 3 (A, B, C, and D) are two sets

FIG. 1 is a schematic ?ow chart of the reactions used to

properties predicted.

of graphs illustrating the undesirable change in animal body

The present compound with its two sulfonate groups was

expected to exhibit improved water solubility but was also
expected to exhibit poor transport across the blood/brain

barrier because of its lipophobic character. However, when
the present compound was made and tested in vivo, it
showed an unexpected increase in e?icacy as compared to
PBN. This increase in efficacy occurred along with an
increase in potency as compared to PBN. In direct contrast
to this marked increase in potency and e?icacy there was a
marked and highly signi?cant decrease in toxicity as com

pared to PBN.
These results were unexpected because in the general

literature on structure/activity relationships within speci?c

thermal regulatory ability which occurs as a function of dose
35

40

the treatment of gradual neurodegeneration conditions (such
as Alzheimer’s disease) as illustrated by their relative ability
to interfere with beta amyloid protein’s inactivation of key
enzymes in solution.
45

The Compound and Salts

de?ned families of compounds therapeutic potency typically
covaries with toxicity. Thus, most related compounds main
tain their ratio of therapeutic potency to toxicity. In contrast,
the compound of this invention deviates from this expected
relationship when its potency increased and its toxicity
decreased relative to closely related analogs.
Accordingly, in one aspect, the invention provides the

level with a prior art nitrone radical trapping agent and
contrasting this with the lack of such undesired toxic effect
with the compound of the invention.
FIG. 4 (A, B, C, and D) is a set of four graphs demon
strating the superiority of the compound of the invention as
compared to a closely related prior art nitrone compound in

The compound of this invention is 2,4-disulfonyl ot-phe
nyl tertiary butyl nitrone. It is also referred to informally
50

herein as “2 4-disulfonyl PBN” or “PBN 2,4-disulfonate.” It
exists in an acid form

PBN-disulfonyl compound
0.

55

|

3031-1

60

and its pharmaceutically acceptable salts.
In a second aspect, the invention provides intravenously

and orally-administrable pharmaceutical compositions hav
ing this compound or its salt as active ingredient.
65
In a third aspect, this invention provides a method for
treating a patient who is suffering from a condition involving

as a solid and in solution in low pH conditions. It also exists
at higher pHs in an ionized salt form which can be shown as

5,488,145
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6

-continued

suitable aqueous or nonaqueous vehicle with buffers, sus

01' HS

pending dispensing agents, colorants, ?avors and the like.
A solid form may include, for example, any of the
following ingredients, or compounds of a similar nature: a
binder such as microcrystalline cellulose, gum tragacanth or
gelatin; an excipient such as starch or lactose, a disintegrat
ing agent such as alginic acid, Primogel, or corn starch; a
lubricant such as magnesium stearate; a glidant such as

0.

where X is a pharrnaceutically acceptable cation. Most
commonly, this cation is a monovalent material such as
sodium, potassium or ammonium, but it can also be a

10

methyl salicylate, or orange ?avoring.
In the case of injectable compositions, they are commonly
based upon injectable sterile saline or phosphate-buffered
saline or other injectable carriers known in the art. Again the
active nitrone is typically a minor component, often being
from about 0.05 to 10% by weight with the remainder being
the injectable carrier and the like.

multivalent alone or cation in combination with a pharma

ceutically acceptable monovalent anion, for example cal
cium with a chloride, bromide, iodide, hydroxyl, nitrate,
sulfonate, acetate, tartrate, oxalate, succinate, palmoate or
the like anion; magnesium with such anions; zinc with such
anions or the like. When these combinations of a polyvalent
cation and a monovalent anion are illustrated in structural

formulae, herein, the monovalent anion is identi?ed as “Y”.

Among these materials, the free acid and the simple

20

sodium, potassium or ammonium salts are most preferred

with the calcium and magnesium salts also being preferred
but somewhat less so.

Compound Preparation

25

tertiary butyl nitrate (Z-methyl-Z-nitropropane) is converted
to the corresponding n-hydroxyl amine using a suitable
catalyst such as an activated zinc/acetic acid catalyst or an

aluminum/mercury amalgam catalyst. This reaction can be
carried out in 0.5 to 12 hours and especially about 2 to 6
35

liquid reaction medium such as alcohol/water mixture in the
case of the zinc catalyst or an ether/water mixture in the case

In the second step, the freshly formed hydroxylamine is

The conditions treated with the 2,4-disulfonyl PBN gen
erally fall into two groups. The ?rst includes conditions
involving acute intense oxidative damage to a region of the
central nervous system. Examples of these conditions
include stroke, conditions associated with stroke, concus
drug into the patient’ s bloodstream as quickly and directly as
possible. This usually means intravenous administration.
Intravenous dose levels for treating these conditions range
from about 0.1 mg/kg/hour to at least 10 mglkg/hour, all for
from about 1 to about 120 hours and especially 24 to 96
hours. A preloading bolus of from about 10 to about 500 mg
may also be administered to achieve adequate steady state
levels.

An unexpected and key advantage of 2,4-disulfonyl PBN

of the aluminum amalgam catalyst.

reacted with 4-formyl-1,3'benzenedisulfonic acid, typically

Conditions Treated and Treatment Regimens

sion and subarachnoid hemorrhage. In this setting, the
compound is administered in manners designed to get the

As detailed in FIG. 1 and demonstrated in Example 1, the
compound of this invention can be prepared by a two step
reaction sequence. In the ?rst step, commercially available

hours or so at a temperature of about 15° to 100° C. in a

colloidal silicon dioxide; a sweetening agent such as sucrose
or saccharin; or a ?avoring agent such as peppermint, sugar,

40

with a slight excess of the amine being used. This reaction
can be carried out at similar temperature conditions. This

is that it can be administered at vastly higher levels than are
possible with PBN itself. As will be shown in the Examples,
doses of up to 1000 mg/kg/hour and higher or intravenous
bolus doses of from 10 to 2500 mg/kg have been demon
strated to be possible with PBN-2,4-disulfonyl or its salts
while with PBN itself death or acute toxicity results from

reaction is generally complete in 10 to 24 hours.
The product so formed is the free acid and is characterized 45 such doses. With 2,4 disulfonyl PBN there is an unexpected
positive continuance of the dose/response curve in these
by a molecular weight of 89 g/mole. It is a white powdery
high dose levels with the clear message that intense heavy
material which decomposes upon heating. It is characterized
dosing immediately post stroke or other trauma may in many
by a solubility in water of greater than 1 gram/m1 and a 1H
cases provide a major positive impact upon recovery.
NMR spectrum in D20 of 8.048 ppm (dd, 8.4, 1.7 Hz); 8.836
The second group of conditions which respond favorably
ppm (d, 8.4 Hz); 8.839 ppm (d, 1.7 Hz); 8.774 ppm (s). 50
to
2,4-disulfonyl PBN treatment are conditions character
The various salts can be easily formed by admixing the
ized by protracted low grade oxidative stress upon the
free acid in aqueous medium with two equivalents of the
central nervous system and gradual progressive central
appropriate base, for example, KOH for the potassium salt,
nervous system function loss. These conditions include
and the like.
55

Pharmaceutical Compositions

Alzheimer’s disease, Parkinson’s disease, amyotrophic lat
eral sclerosis (ALS), mu1ti~infarct dementia, retinopathy and

the like. Each of these conditions is characterized by a
progressive loss of function. 2,4-disulfonyl-PBN or its salts,
when administered orally or intravenously, can slow and
injection administration
60 possibly reverse the loss of function. If intravenous admin
istration is desired, similar levels to those used with acute
The compositions for oral administration can take the
conditions but at the lower end of the ranges are generally
form of liquid solutions or suspensions, powders, tablets,
used.
capsules or the like. In such compositions, the PBN 2,4
In these cases, the regimen for treatment may stretch over
disulfonate or its salt is usually a minor component (0.1 to
say 50% by weight) with the remainder being various 65 many months or years so oral dosing is preferred for patient
convenience and tolerance. With oral dosing, one to three
vehicles or carriers and processing aids helpful for forming
oral doses per day, each from about 0.02 to about 50 mg/kg
the desired dosing form. A liquid form may include a

The compound (including its salts) can be formulated into
pharmaceutical compositions suitable for oral or intravenous

5,488,145
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8

are called for with preferred doses being from about 0.04 to

a Friedrichs condenser cooled with recirculating ice

about 5.0 mg/kg.

water.

2. To the ?ask were added 200 mL of methanol, 4-forrnyl

Of course, one can administer 2,4-disulfonyl PBN as the
sole active agent or one can administer it in combination

1,3-benzenedisulfonic acid (9.31 g, 30 nnrroles) and
N-t-butylhydroxylamine (25 mL of the methanol solu
tion from part A, 30 mmoles theoretical).

with other agents.
EXAMPLES

3. The reaction was heated to re?ux with a heating mantle

EXAMPLE 1

4. The mixture was re?uxed for 2 hours.

While bubbling the reaction with nitrogen with stirring.
1O

5. The remainder of hydroxylamine from part A was
added.
6. Re?uxing was continued with nitrogen bubbling for at
least 18 hours, but not more than 24 hours.

Synthesis of 2,4-disulfonylphenyl-N-t~butylnitrone
(Compound “I” in subsequent Examples). This preferred
synthesis is based on the work by R. H. Hinton and E. G.

Janzen (J. Org. Chem. 57:2646-2651, 1992). As shown in

FIG. 1 it involves the condensation of an aldehyde with a 15

7. The hot reaction mixture was ?ltered on a Buchner

hydroxylamine. The hydroxylamine is unstable and is pre

funnel, and the solid washed with hot methanol.
8. The methanol was stripped off by rotary evaporation to

pared fresh on the day of use using an activated zinc catalyst.
The synthesis is as follows:

Prerequisite Chemicals

20

1. 95% Ethanol

2. 2-Methyl-2~nitropropane
3. Zinc dust
4. Glacial acetic acid
. Diethyl ether

25

7. Magnesium Sulfate, Anhydrous solid
8 4-Formyl-l,3-benzenesulfonic acid (MW 310.21
g/mole), disodium salt, hydrate

EXAMPLE 2

Alternate Synthesis of 2,4-disulfonylphenyl-N-t-butylni
trone (Compound 1). This is an earlier-developed method
which used to prepare samples of the compound used in

9. Methanol
10. Dichloromethane
Procedure

several of the experiments reported in the Examples of this
speci?cation. The product of this Example is identical in all
35

1. A 500 mL three neck round bottom ?ask is equipped
with a magnetic stir bar, thermometer adapter, ther
mometer, and addition funnel.
2. 95% ethanol (350 mL) was added to the ?ask and

ways to the product of Example 1. This synthesis method is
as follows:

Prerequisite Chemicals
1. Aluminum Foil, cut into 5 cm wide strips and rolled in
a ca. 1 cm diameter cylinder

cooled to 10° C. in an ice bath.

2. Mercury (H) Chloride (9.68 g in 476 ml water)

3. 2-Methyl-2-nitropropane (6.18 g, 0,060 mole), and zinc
dust (5.89 g, 0,090 mole) were added in single portions.
4. Glacial acetic acid (10.8 g, 0,180 mole) was placed in

3. Ethanol

4. Ether (6 L)
. Pure Water

the addition funnel and added dropwise at such a rate

with vigorous stirring to maintain the temperature

12. The reaction typically gives 75% yield of I, a white

powder.

6. Saturated sodium chloride

Preparation of N-t-Butylhydroxylamine

a yellow, viscous oil.
9. Hot 1:1 ethanol:acetone (200 mL) was added and the
mixture heated to dissolve the oil.
10. The solution was cooled to crystallize the product.
11. The product was collected on a Buchner funnel and
dried under vacuum overnight.

45

below 15° C.

. 2-Methyl-2-nitropropane

. Sodium Hydroxide, 2M (80 g in 1 L water)
. Magnesium Sulfate, Anhydrous solid

5. The ice bath was removed and mixture was stirred for
3 hrs at room temperature.

4-Formyl-1,3-benzenesulfonic acid (MW 310.21

6. The solvent was stripped from the mixture, leaving
t-butylhydroxylamine, zinc acetate, and water.
7. Dichloromethane (50 mL) was added and the mixture
?ltered through a Buchner funnel.

g/mole)
Procedure

Preparation of N-t~Butylhydroxylamine

55
with 2X25 mL dichloromethane.
9. Water was separated from the ?ltrate in a separatory

1. Aluminum foil cylinders were dipped into HgCl2
solution for 15—30 seconds, then dipped in ethanol,
then dipped in ether and then placed into a 5L ?ask
containing 500 ml of diethyl ether and 21.4 ml of water.

funnel and the organic layer dried over magnesium

2. The ?ask was ?tted with a 250 ml pressure-equalizing

8. The zinc acetate cake left on the ?lter paper was washed

sulfate.

10. The magnesium sulfate was removed by ?ltering
through ?uted ?lter paper, then dichloromethane

dropping funnel, a mechanical stirrer, a nitrogen inlet,
60

stripped oil" by rotary evaporation.

4. 2-Methyl-2-nitropropane (71.68 g, 75.5 ml) was added

was dissolved in methanol (50 mL) for use in part B.
l. A 3-neck 250 ml round bottom ?ask was set up with a

stir bar, a gas dispersion tube, an addition funnel, and

water.

. The mixture was stirred for 10 minutes.

11. The product (100% yield=5.34 g), a viscous liquid,

Preparation of 2,4-disulfonylphenyl-N-t-butylnitrone

and a Friedrichs condenser cooled with recirculated ice

65

using the dropping funnel at such a rate as to maintain
a vigorous re?ux.

NOTE: Addition must be completed in less than 20

minutes or the yield drops signi?cantly.

5,488,145
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neural protection for compound I compared to PBN and two
closely related analogs and an unexpected decrease in tox
icity compared to PBN.

5. As the addition proceeded, ether was added in 500 ml
portions. This was done to maintain as high a concen

tration of product as possible without the formation of
a gel. Up to 2 L of ether can be added with no
deleterious effects on the yield.
6. Once addition of 2-methyl-2-nitropropane was com
plete, the reaction was stirred for an additional 30
minutes.
7. The resulting gray suspension was suction ?ltered in 3

TABLE 1
Neuronal nuclei/100 micron ?eld

PBN

2sulfo

3
sulfo

I.

4.21

4.21

4.21

4.21

(.43)

(.43)

(.43)

(.43)

Ischemic control

0.58

0.58

0.58

0.58

(.28)

(.28)

(.28)

(.28)

3.2 mg/kg

0.43

0.73

0.35

1.43

(.18)

(.34)

(.21)

(.31)

10 mg/kg

1.13

0.68

0.81

2.57

(.39)

(.31)

(.40)

(.25)

could be dried further in a vacuum oven (no more than

32 mg/kg

1.83

0.73

1.63

3.53

a few minutes), leaving 38 to 45 g of solid.

(.21)

(.31)

(.35)

(.41)

50 mg/kg

3.11

1.01

1.63

4.11

(.29)

(.61)

(.35)

(.43)

100 mg/lcg

3.68

0.93

1.93

4.18

(.71)

(.53)

(.39)

(.49)

320 mg/kg

3.78

1.11

1.78

4.23

(.43)

(.41)

(.40)

(.39)

1000 mg/kg

Toxic

0.98

1.58

4.11

(43)

(33)

3200 mg/kg

Toxic

—

—

batches to remove aluminum salts.
8. Each ?lter cake was washed with 1 L of ether.

10

9. The combined either layers were washed with 300 ml
of 2 M NaOH, then dried (MgSO4), and concentrated
in vacuo to leave a soft white solid.

15

Non-ischernic control

10. The solid melts just above room temperature, but

11. The solid can be used as is or was puri?ed by

recrystallization from pentane.
12. Molecular weight-89 g/mole.
B. Preparation of 2,4-disulfonylphenyl-N-t-butylnitrone

20

1. A 250 m1 ?ask was equipped with a stir bar and a
Friedrichs condenser cooled with recirculated ice 25

(41)
4.18

water.

2. The ?ask was charged with 71.8 ml of methanol, 14.5

g of 4-formyl-1,3-benzenedisulfonic acid (46.7
mmoles, 1 eq.), and 5.0 g of N-t-butylhydroxylamine

(56.2 mmoles, 1.2 eq.).

EXAMPLE 4
30

3. The mixture was re?uxed overnight.
4. The reaction product was transferred to round-bottom

post-ischemia treatment. The general method described in
example 1 was used but the test compounds were adminis
tered i.p. as a single dose 30 min after reperfusion following

?ask and rotovaped to dry.
5. The solid residue was mashed with ether, the ether was

decanted off (yellow).
6. Step 5 was repeated.
7. Product (“I”) was crystallized from methanol following

35

5 min ischemia. The results are summarized in Table 2. They
show that the compound of the invention is again more
potent at low doses and more potent and less toxic at high

doses. Also again, toxicity interferes with the prior art
materials ability to go to high doses at which levels the

a hot methanol ?ltration to remove insoluble precipi

tates and recrystallized twice from methanol.

A series of experiments were conducted in which com
pound I was compared to PBN and two sulfonate analogs in

40

compound of the invention provides dramatically effective

therapy.
TABLE 2

EXAMPLE 3

Neuronal nuclei/100 micron ?eld

A series of experiments were carried out to compare in

vivo the ef?cacy of 2,4 disulfonyl PBN (“I”), PBN, and two
monosulfonate PBN compounds as agents for protecting
against neuron loss following brain ischernia and reperfu
sion injury. The test procedure is that reported by W. Cao, J.

45

2sulfo

3—
sulf

I.

4.18

4.18

4.18

4.18

(.59)

(.59)

(.59)

(.59)

Isohemie control

0.85

0.85

0.85

0.85

(.19)

(.19)

(.19)

(.19)

32 mg/kg

1.09

ND

ND

1.83

50 mglkg

1.85

0.68

0.73

2.73

(.49)

(.31)

(.34)

(.39)

100 mg/kg

2.11

0.78

1.09

3.41

(.51)

(.23)

(.48)

(.37)

320 mg/kg

2.25

0.81

0.93

3.55

(.43)

(.31)

1000 mg/kg

Toxic

ND

ND

3.68

Non-ischemic control

M. Carney, A. Duchon, R. A. Floyd and M. Chevion as

“Oxygen free radical involvement in ischemia and reperfu
sion injury to brain, Neuroscience Letters, 88 (1988), 233. In

PBN

50

(.31)

the experiments a test compound was administered to groups

of six gerbils i.p. as a single dose 30 min before 5 min
bilateral carotid occlusion. The density of neuronal nuclei in
a 100 micron was measured. Two controls were present— 55

controls which received no test compound and controls
which received no test compound and no brain ischemia. As

illustrated in Table 1. the compound of the invention showed
unexpected advantages as compared to the prior art mate

(.41)

(.48)
(.39)

rials. First, it was seen that at low dose levels, such as 3.2 60

mg/kg, compound I was 2—3 times as potent at preventing

EXAMPLE 5

neuronal loss. At high does levels it was seen that I was able

to achieve complete protection against neuronal loss as the
test brains showed neuronal densities identical to the non—

ischernic controls. The prior materials were either toxic at
these dose levels or showed signi?cantly lower degrees of
protection. These results show a clear increase in potency for

65

Compound I was compared with PBN to determine their
relative effectiveness for protection of neuronal loss when
administered i.v. 60 min after reperfusion onset following 5
min ischemia in gerbils using the general test method
described in Example 1.. The results are summarized in

5,488,145
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Table 3. and illustrate that compound I is of signi?cantly
greater therapeutic bene?t in a clinical treatment setting

TABLE 5-continued

following injury to the brain.

Posttreatment

TABLE 3
mg/kg single dose
N = 6 per group
Saline, no ischemia

0.0

0.5

1.0

10

4.11

-

_

_

—

_

_

0.83

1.07

1.23

(.23)

(.29)

(.31)

1.25

1.75

2.43

(.19)

(.28)

(.31)

(.28)
saline, ischemia

0.93

(mg/kg/hr)

0.0

1.0

10

PBN

—

17,7

13.8

(2.8)

(2.3)

16.8

12.7

8.3

(1.7)

(3.93)

(.71)

1.

—

—

I.

—

TOXIC

EXAMPLE 8

In this study, compound I and PBN were compared for

their ability to impart lethality protection (% survived) in
aged gerbils (18-24 months of age, n:12/group) from 10
min ischemia when given 30 min before ischemia. As shown
in Table 6. compound I was superior at all dose levels and
achieved complete protection at high levels where PBN was

Neither PBN nor 1. had an effect on neuronal density in

control ‘gerbils without brain injury.
20

EXAMPLE 6

100

10

(-17)
PBN

Infarct Volume in mm3

only partially e?'ective.
TABLE 6

Brain injury can manifest itself as behavioral changes. In

this experiment, young adult (3-4 months of age) gerbils

Pretreatment (mg/kg)

0.0

10

32

100

320

11

_

~

_

-

_
_

42
5o

so
75

75
100

92
100

were tested to determine their ability to perform an 8-arrn
maze test 24 hours following an ischemic event as described 25

Saline

in Example 1. As compared to nonischemic animals, when

PBN
I.

untreated they committed many more errors. PBN and
compound 1 were administered to some of the test animals.

As detailed in Table 4. gerbils treated with high doses of
compound I had error levels indistinguishable from those of
nonischemic animals. PBN was less effective. This shows
that compound I can protect against the loss of temporal/

An important advantage of the compound of this inven
tion as compared to the art-taught compound, PBN, is its
markedly diminished toxicity. As detailed in Table 7. acute

spatial short term memory following ischemia (24 hours
post) errors in 8-arm radial maze test of young gerbils

lethality in C57BL/6L mice was determined based upon

following 5 min ischemia.

35

TABLE 4

Control

0.0

1.0

4.1

32

50

TABLE 7

100

——

—

—

—

—

—

% Survival

(38)
Postischemic

37.6

(4.85)
PBN
I.

—
—

varying sizes of single i.p. doses of nitrone. PBN showed
signi?cant toxicity at 560 mg/kg dose levels. Compound I
showed no toxicity at doses nearly twenty times as great.

mg/kg/hr for 24 hours
N = 6 per group

EXAMPLE 9

30

29.8

18.19

6.23

5.83

(7.27)

(5.83)

(.71)

(.49)

14.63

7.19

4.28

4.11

(3.81)

(.81)

(.29)

(.19)

45

mg/kg

n = 20 mice

320

560

1000

3000

10000

PBN
I.

100
100

25
100

0
100

0
100

0
100

EXAMPLE 10

EXAMPLE 7

50

The ability of the compound of the invention to reduce
infarct volume following an ischemic event was determined.
As detailed in Table 5. it was observed that while PBN and

Another undesirable systemic effect which has been
observed in vivo with nitrone radical traps is a depression in
body temperature. This toxicity can have serious health
consequences and also can complicate diagnosis of other
conditions. As detailed in FIGS. 2 and 4, the compound of

compound I were both e?fective at low doses, at high doses
this invention was administered to mice and gerbils at levels
I gave the best protection and PBN was toxic. Table 5 shows 55 as high as 1000 mg/kg with no measurable temperature
the infarct volume observed when test compound was
decrease. In contrast, the compound of the art, PBN, gave up
administered i.v. 60 min after middle cerebral occlusion and
to an 8° C. decrease in body temperature at a does of only
continued for 24 hours in C57BL/6J mice.
500 mg/kg.
TABLE 5
Posttreatment
(mg/kg/hr)
Control, no ischemia
Saline, ischemia

60

EXAMPLE 11

Infarct Volume in mm3
0.0

1.0

10

0

_

_

_

23

_

_.

__

(2)

The compound of the invention was tested to determine
its effectiveness in the treatment of conditions characterized

100
65

by protracted low grade oxidative stress upon the central
nervous system and gradual progressive central nervous
system function loss by testing its effectiveness in a model
for Alzheimer’s disease (“AD”). This model has the follow

5,488,145
14

13
What is claimed is:

ing basis: Recent studies have demonstrated that there is an

1. 2,4-disulfonyl ot-phenyl tertiary butyl nitrone.

age-associated increase in protein oxidation and loss of
enzyme activities in the brain of aged individuals. Tissue
cultures of fibroblasts from aged individuals and red blood
cells of different ages both show an exponential increase in

2. A compound de?ned by the formula:
0.

protein carbonyl content (a measure of protein oxidation)

H035

l
CHZNT C(CH3)3.

and a decrease in marker enzyme activities. Brain protein
oxidation progressively increases over the life span of the
individual.

The role of abnormal arnyloid precursor peptide process
ing and metabolism in AD has also been explored in a
number of different models. In vitro studies using embryonic

3. A pharmaceutically acceptable salt of
O_

hippocampal neuronal and neuronal/glial cultures have dem
onstrated that BAP 1-40 produces cytotoxicity over an

extended period of co-incubation. When this peptide is

15

infused into rat brains, lesions are produced. Some of the

proposed breakdown fragments of BAP are also neurotoxic
[c.g. BAP (25-35)]. The neurotoxicity appears to be both
mediated via glutamate receptors, and also by non-glutamate
receptors mechanisms. Confocal microscopy studies of neu
ronal cultures have demonstrated that exposure to BAP
(1-40) results in oxidative stress [Dichloro?uorescein and
increased intracellular free calcium Fura-Z].
In our model it has been demonstrated that BAP fragments
can directly inactivate glutamine synthetase (GS) and cre~
atine kinase (CK) in tissue extracts and in cultured hippoc
ampal neurons and glia (See A and B in FIG. 4). A and B of
FIG. 4 present the dose-related inactivation of glutamine

synthetase and creatine kinase by AP (25-35). Cytosolic

4. The salt of claim 3 having the formula:
0,

I

wherein X is selected from the group consisting of Na, K,
NH4, Ca, Mg, Zn, ZnY, CaY and MgY, wherein Y is a
pharmaceutically acceptable monovalent anion.
5. A pharmaceutical composition comprising the com
pound of claim 1 in a pharmaceutically acceptable intrave

fractions from gerbil neocortex were prepared and enzyme 30
activities determined. Samples were incubated in the pres
nous injectable carrier.
ence of di?erent concentrations of the peptide for 10 min
6. A pharmaceutical composition comprising the com
prior to assay. Solid symbols represent the effects of the
pound of claim 1 in a pharmaceutically acceptable oral
naturally occurring 25—35 fragment. Open circles indicate
carrier.
35

that the reverse sequence (32-25) had no effect on enzyme

activity. Open triangles indicate that the scrambled amino
acid sequence also had no elfect on enzyme activities,

compared to the effect of 25—35. Each point is the mean (+/—
s.e.) of 5 observations. BAP derived and other cellular

sources of free radicals are an important detenninant of the 40

initiation and progression of AD.
As demonstrated in C and D in FIG. 4, compound 1 and
PBN each show the ability to protect GS and CK against the
effects of BAP fragments. C and D of FIG. 4 present the
protective effects of co-incubation of the cytosolic fractions
with BAP 25-35 (0.4 mg/ml) in combination with different
concentrations of PBN (open circles) or compound I (closed
circles). Each point is the mean (+/— s.e.) of 3 observations.
As can be seen in C and D, compound I gives complete
protection and in fact might even be able to reverse the
effects of oxidation. In contrast, PBN’s effectiveness is quite
limited as it is asymptotically leveling out at a substantially

incomplete level of protection.

7. A pharmaceutical composition comprising the com
pound of claim 2 in a pharmaceutically acceptable intrave
nous injectable carrier.
8. A pharmaceutical composition comprising a compound
of claim 2 in a pharmaceutically acceptable oral carrier.
9. A phannaceutical composition comprising the com
pound of claim 3 in a pharmaceutically acceptable intrave
nous injectable carrier.

10. A pharmaceutical composition comprising the com
pound of claim 4 in a pharmaceutically acceptable intrave
nous injectable carrier.

11. A pharmaceutical composition comprising a com
pound of claim 3 in a pharmaceutically acceptable oral
carrier.

12. A pharmaceutical composition comprising a com
pound of claim 4 in a pharmaceutically acceptable oral
carrier.

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION
PATENTNO_
DATED

5,488,145
:

INVENTOR(S> 1

Page 1 of 4

January 30, 1996
JOHN M. C‘ARNEY

It is certified that error appears in the above-indenti?ed patent and that said Letters Patent is hereby
corrected as shown below:

Title
IN TH Ea?’
ITLE:

'
Item [54]
and col. 1,
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—-2,4—Disulfo Phenyl Butyl Nitrone, Its Salts And Their
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read —-2,4-Disulfo or -phenyl‘ tertiary butyl nitrone-—.
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disulfo--.

UNITED STATES PATENT ANDTRADEMARK OFFICE

CERTIFICATE OF CORRECTION
PATENTNQ.
DATED

5,488,145
January 30, .1996

|NVENTOR(S) ;

JOHN M. CARNEY

Page 2 of 4

It is certified that error appears in the above-indentified patent and that said Letters Patent is hereby
corrected asshown below:

Column 3, line 53, "PBN-disulfonyl" should read --PBN
disulfo--.

Column 4, line 47, "2,4-disulfonyl" should read -—2,4
disulfo—-.
Column 4, line 49, "2,4-disulfonyl PBN" should read
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Column 6, line 44,
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